Hengrui Medicine gains approval for new anesthetic indication
Jiangsu Hengrui Medicine announced that its Bupivacaine Liposome Injection has been approved for expanded use, specifically for postoperative regional analgesia following popliteal sciatic nerve block and adductor canal block in adults. The drug, already approved in China in December 2022 for postoperative local analgesia via single-dose infiltration in patients aged 12 and older, and for postoperative regional analgesia following interscalene brachial plexus block in adults, has also received approval in the United States in July 2024. Bupivacaine Liposome Injection, using an advanced multi-vesicular liposome drug delivery system, offers prolonged pain relief compared to conventional formulations. Global sales of bupivacaine liposome related formulations reached USD 633 million in 2024. Hengrui Medicine has invested approximately CNY 85.21 million in the research and development of this project. The company cautioned investors about potential uncertainties in production and sales following the approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime